Biomarin Pharmaceutical (BMRN) Other Non-Current Assets (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Other Non-Current Assets came in at $276.4 million in Q1 2026, up 17.3% YoY from $235.7 million in Q1 2025, and little changed on a QoQ basis from $277.0 million in Q4 2025.
Biomarin Pharmaceutical (BMRN) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Other Non-Current Assets data on file, last reported at $276.4 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 17.3% year-over-year to $276.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $276.4 million (up 17.3% YoY) and the FY2025 annual result came in at $277.0 million, up 10.21% from the prior year.
- Other Non-Current Assets steadied at $276.4 million in Q1 2026, from $277.0 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $277.0 million in Q4 2025 to a low of $144.2 million in Q2 2023.
- A 5-year average of $199.7 million and a median of $184.8 million in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets dropped 5.03% — and 2024, when it surged 46.55%.
- Tracing BMRN's Other Non-Current Assets over 5 years: stood at $176.2 million in 2022, then retreated by 2.67% to $171.5 million in 2023, then surged by 46.55% to $251.4 million in 2024, then gained by 10.21% to $277.0 million in 2025, then fell by 0.23% to $276.4 million in 2026.
- The last three Other Non-Current Assets figures came in at $276.4 million (Q1 2026), $277.0 million (Q4 2025), and $270.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 338.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 338.14 Mn |
| Mar 31, 2026 | 276.42 Mn |
| Dec 31, 2025 | 277.05 Mn |
| Sep 30, 2025 | 270.78 Mn |
| Jun 30, 2025 | 249.19 Mn |
| Mar 31, 2025 | 235.65 Mn |
| Dec 31, 2024 | 251.39 Mn |
| Sep 30, 2024 | 199.31 Mn |
| Jun 30, 2024 | 190.77 Mn |
| Mar 31, 2024 | 184.79 Mn |
| Dec 31, 2023 | 171.54 Mn |
| Sep 30, 2023 | 165.07 Mn |
| Jun 30, 2023 | 144.17 Mn |
| Mar 31, 2023 | 150.06 Mn |
| Dec 31, 2022 | 176.24 Mn |
| Sep 30, 2022 | 151.79 Mn |
| Jun 30, 2022 | 151.80 Mn |
| Mar 31, 2022 | 149.19 Mn |
| Dec 31, 2021 | 152.12 Mn |
| Sep 30, 2021 | 144.71 Mn |